The latest price target for Milestone Pharmaceuticals (NASDAQ:MIST) was reported by HC Wainwright & Co. on January 6, 2026. The analyst firm set a price target for $8.00 expecting MIST to rise to within 12 months (a possible 313.27% upside). 6 analyst firms have reported ratings in the last year.

The latest analyst rating for Milestone Pharmaceuticals (NASDAQ:MIST) was provided by HC Wainwright & Co., and Milestone Pharmaceuticals reiterated their buy rating.

The last upgrade for Milestone Pharmaceuticals Inc happened on December 15, 2025 when TD Cowen raised their price target to $8. TD Cowen previously had a hold for Milestone Pharmaceuticals Inc.

The last downgrade for Milestone Pharmaceuticals Inc happened on June 20, 2023 when Jefferies changed their price target from $8 to $4 for Milestone Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Milestone Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Milestone Pharmaceuticals was filed on January 6, 2026 so you should expect the next rating to be made available sometime around January 6, 2027.

While ratings are subjective and will change, the latest Milestone Pharmaceuticals (MIST) rating was a reiterated with a price target of $8.00 to $8.00. The current price Milestone Pharmaceuticals (MIST) is trading at is $1.94, which is out of the analyst’s predicted range.